Authors: Druker, BJ Talpaz, M Resta, DJ Peng, B Buchdunger, E Ford, JM Lydon, NB Kantarjian, H Capdeville, R Ohno-Jones, S Sawyers, CL

Citation: Bj. Druker et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinasein chronic myeloid leukemia., N ENG J MED, 344(14), 2001, pp. 1031-1037

Authors: Buchdunger, E Cioffi, CL Law, N Stover, D Ohno-Jones, S Druker, BJ Lydon, NB

Citation: E. Buchdunger et al., Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors, J PHARM EXP, 295(1), 2000, pp. 139-145

Authors: Druker, BJ Lydon, NB

Citation: Bj. Druker et Nb. Lydon, Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia, J CLIN INV, 105(1), 2000, pp. 3-7

Authors: Shen, ZW Batzer, A Koehler, JA Polakis, P Schlessinger, J Lydon, NB Moran, MF

Citation: Zw. Shen et al., Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src, ONCOGENE, 18(33), 1999, pp. 4647-4653

Authors: Toledo, LM Lydon, NB Elbaum, D

Citation: Lm. Toledo et al., The structure-based design of ATP-site directed protein kinase inhibitors, CURR MED CH, 6(9), 1999, pp. 775-805